Helix BioPharma Appoints New CEO to Accelerate Oncology Drug Development

Helix BioPharma Corp. has appointed Dr. Thomas Mehrling as its new Chief Executive Officer, signaling a strategic leadership transition aimed at advancing the company's oncology research and drug development pipeline. Dr. Mehrling, a distinguished hemato-oncologist and pharmacologist with more than 20 years of international pharmaceutical experience, will lead the company's efforts to develop innovative cancer treatments.

With a proven track record of building successful global oncology businesses, Dr. Mehrling brings extensive expertise from leadership roles at Mundipharma International Ltd. and previous medical research positions. His background includes introducing groundbreaking cancer drugs across Europe that generated nearly USD 1 billion in sales and establishing specialized oncology research initiatives.

The leadership change comes with significant strategic objectives for 2025 and beyond. Dr. Mehrling plans to advance the company's lead candidate, L-DOS47, by initiating a Phase II study in combination with pembrolizumab for non-small cell lung cancer treatment. This approach represents a potentially transformative strategy in addressing challenging solid tumor environments.

Helix BioPharma's focus remains on developing novel therapies targeting hard-to-treat cancers, with a specific emphasis on their proprietary bio-conjugate technology platform. The company's innovative approach centers on neutralizing tumor microenvironments and enhancing anti-cancer immune responses through precision-targeted treatments.

Outgoing CEO Jacek Antas will continue to serve as Chairman, supporting the company's transition and strategic vision. The leadership change reflects Helix BioPharma's commitment to building an agile, resilient organization capable of delivering advanced oncological research and potential breakthrough treatments.

Dr. Mehrling's appointment underscores the company's determination to accelerate clinical development and bring innovative cancer therapies to patients. By leveraging his extensive pharmaceutical and medical research background, Helix BioPharma aims to advance its pipeline of drug candidates and address critical unmet needs in cancer treatment.